Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Hanauer

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Gastroenterology|October 9, 2007
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitisScott Plevy, Bruce Salzberg, Gert Van Assche, et al.
Gastroenterology|July 8, 2008
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitisBruce E Sands, William J Sandborn, Brian Feagan, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.
Crohn'S & Colitis 360|February 13, 2023
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug MonitoringAmy Hemperly, Marla C Dubinsky, Andres Yarur, et al.
Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Gastroenterology|October 9, 2007
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitisScott Plevy, Bruce Salzberg, Gert Van Assche, et al.
Gastroenterology|July 8, 2008
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitisBruce E Sands, William J Sandborn, Brian Feagan, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.
Journal of Crohn'S & Colitis|December 14, 2023
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's DiseaseSéverine Vermeire, Silvio Danese, William J Sandborn, et al.
Inflammatory Bowel Diseases|May 20, 2015
Briakinumab for treatment of Crohn's disease: results of a randomized trialRemo Panaccione, William J Sandborn, Glenn L Gordon, et al.
Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.
Crohn'S & Colitis 360|February 13, 2023
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug MonitoringAmy Hemperly, Marla C Dubinsky, Andres Yarur, et al.
Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.
Pageof 7